Experience Matters.

Lawrence Blatt

Non-Executive Director

Co-founded Alios BioPharma, Inc., and led the company from inception to acquisition by Johnson & Johnson.

Iain D. Dukes

Non-Executive Director

Holds multiple Board/CEO positions, alongside world-class licensing experience including at Merck & Co. and Amgen Inc.

Ron Hunt

Managing Director, New Leaf Venture Partners

Founder of New Leaf Venture Partners with over 20 years investment and company-building experience.

Richard N. Kender

Non-Executive Director

Involved in over 100 Business Development & Corporate Licensing transactions during 35 year tenure at Merck & Co.

Chau Q. Khuong

Private Equity Partner, OrbiMed

Experienced investor focused on structured investments across private and public biopharmaceutical and medical device companies.

Nanna Lüneborg

Partner, Novo Holdings

Highest quality investments including successful public listings of Orphazyme (ORPHA) and ObsEva (OBSV).

Dr. Ken Powell

Chairman

Founded and led Arrow Therapeutics Ltd to $150 million acquisition by AstraZeneca.

Alex C. Sapir

Chief Executive Officer

Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.

Raphaël Wisniewski

Partner, Andera Partners

Top pedigree investments, IPOs and trade sales over 19 years with Andera Partners.

Dr. Stuart Cockerill

Chief Scientific Officer, Founder

Spearheaded the GSK erbB2 Oncology Project Team that discovered Tykerb™ for metastatic breast cancer.

Dr. Rachel Harland

Head of Preclinical Development

Built value for two top-tier biotech companies via pivotal drug development strategies.

Dr. Seth Hetherington

Chief Medical Officer

Word class pediatric infectious disease physician – led clinical development of multiple therapeutic vaccines at Genocea Biosciences.

Dr. Eddy Littler

Chief Operating Officer

Led the identification and development of OlysioTM for chronic hepatitis C virus.

Dr. Neil Mathews

Project Director, Founder

Led deal-critical Hepatitis C project at Arrow Therapeutics prior to acquisition by AstraZeneca.

Alan A. Musso

Chief Financial Officer

Secured $150M financing and prepared Peloton Therapeutics for IPO — laying groundwork for Merck & Co. acquisition.

Alex C. Sapir

Chief Executive Officer

Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.

Dr. Elaine Thomas

Head of Virology

Advanced from Harvard Medical School post-doctoral fellowship to lead multiple preclinical & clinical virology studies.